Kiniksa Pharmaceuticals International (KNSA) Interest Expenses (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Interest Expenses of $680000.0 for Q1 2026, up 67900.0% on a QoQ basis from $1000.0 in Q4 2025, and up 22566.67% year-over-year from N/an in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Interest Expenses (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Interest Expenses history runs 10 years deep, the most recent figure standing at $680000.0 for Q1 2026.
- Quarterly Interest Expenses rose 22566.67% year-over-year to $680000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $680000.0 (up 22566.67% YoY) and the FY2025 annual result came in at $213.3 million, down 67.52% from the prior year.
- Interest Expenses was $680000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, up from $1000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $62.3 million in Q4 2024 and bottomed at $1000.0 in Q4 2025.
- A 5-year average of $13.0 million and a median of $353000.0 in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2025 — Interest Expenses sank 100.0% — and 2026, when it soared 22566.67%.
- Kiniksa Pharmaceuticals International's Interest Expenses stood at $19.6 million in 2022, then surged by 179.07% to $54.7 million in 2023, then increased by 14.05% to $62.3 million in 2024, then sank by 100.0% to $1000.0 in 2025, then jumped by 67900.0% to $680000.0 in 2026.
- Business Quant data shows KNSA's Interest Expenses at $680000.0 in Q1 2026, $1000.0 in Q4 2025, and $11000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.77 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.78 Bn | 4.31 Bn | 193.47 Mn | 680,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 680,000.00 |
| Mar 31, 2026 | 680,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 62.33 Mn |
| Dec 31, 2024 | 62.33 Mn |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Dec 31, 2023 | 54.65 Mn |
| Dec 31, 2023 | 54.65 Mn |
| Sep 30, 2023 | 2.95 Mn |
| Sep 30, 2023 | 2.95 Mn |